CytoMed Therapeutics (GDTC) Non-Current Assets (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Non-Current Assets for 5 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 15.33% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Dec 2025, up 15.33% year-over-year, with the annual reading at $3.4 million for FY2025, 12.9% up from the prior year.
  • Non-Current Assets hit $3.3 million in Q4 2025 for CytoMed Therapeutics, up from $2.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $3.3 million in Q4 2025 to a low of $1.7 million in Q4 2023.
  • Historically, Non-Current Assets has averaged $2.4 million across 5 years, with a median of $2.1 million in 2021.
  • Biggest five-year swings in Non-Current Assets: decreased 14.54% in 2023 and later surged 71.8% in 2024.
  • Year by year, Non-Current Assets stood at $2.1 million in 2021, then decreased by 4.58% to $2.0 million in 2022, then fell by 14.54% to $1.7 million in 2023, then soared by 71.8% to $2.9 million in 2024, then rose by 15.33% to $3.3 million in 2025.
  • Business Quant data shows Non-Current Assets for GDTC at $3.3 million in Q4 2025, $2.9 million in Q4 2024, and $1.7 million in Q4 2023.